Raise closed, search for fresh raises on Seedstage

Bryan, TX

Advancing clinical trials for a breakthrough antifungal treatment addressing drug-resistant infections.

• Breakthrough antifungal treatment: Occidiofungin addresses drug-resistant fungal infections with a novel mechanism of action.
• FDA designations: Fast-track and QIDP status highlight the treatment’s potential and extend patent protection.
• Clinical progress: Successfully completed part of Phase 1 trials with favorable safety data.
• Market opportunity: Positioned to address a multi-billion-dollar unmet need in antifungal treatments.
• Robust pipeline: Developing solutions for additional fungal infections and resistant bacterial strains.

Sano Chemicals is at the forefront of antifungal innovation with its flagship product, Occidiofungin – The Fungus Killer™, targeting the pressing issue of drug-resistant fungal infections, including recurrent vulvovaginal candidiasis (RVVC). With FDA Fast-track and Qualified Infectious Disease Product (QIDP) designations, Occidiofungin offers a novel mechanism of action that effectively eliminates fungal infections while preserving beneficial microbiota. The company has successfully completed the first part of Phase 1 FDA human trials, demonstrating a favorable safety profile and laying the groundwork for further clinical development. The treatment addresses an unmet need for effective, low-toxicity solutions for fungal infections, especially RVVC, which affects up to 9 million women annually in the U.S.

Funds raised will propel Phase 1 and 2 clinical trials, support the development of complementary products, and enhance commercialization efforts. Sano Chemicals is strategically positioned to enter the multi-billion-dollar U.S. market for antifungal treatments, providing a vital alternative to current therapies. With a robust pipeline and strong industry interest, the company is poised to make a significant impact in women’s health and the broader healthcare landscape.

Company Info

Sano Chemicals is developing Occidiofungin, a groundbreaking antifungal drug aimed at treating recurrent and drug-resistant vaginal yeast infections.

Sano Chemicals is focused on pioneering antifungal innovation with its flagship product, Occidiofungin – The Fungus Killer™, which aims to address the growing problem of recurrent vulvovaginal candidiasis (RVVC), a condition affecting millions of women globally. The drug is currently undergoing Phase 1 FDA human trials, with promising results indicating its potential to effectively treat RVVC, especially drug-resistant strains. Occidiofungin has received FDA Fast-track and Qualified Infectious Disease Product (QIDP) designations, allowing for accelerated approval processes and extended patent protection. The company’s goal is to revolutionize the treatment of vaginal yeast infections, addressing the $4–5 billion U.S. market, with further expansion potential.

In addition to its clinical progress, Sano Chemicals has secured substantial interest from major pharmaceutical companies, such as Organon, indicating the market’s demand for new, effective treatments. The product works by targeting all resistant candidal species without harming beneficial microbiota, offering a safer and more effective alternative to current treatments. The company plans to complete Phase 2 clinical trials within the next few years and pursue partnerships with pharmaceutical companies to bring the drug to market. Sano Chemicals aims to capture a significant share of the growing antifungal market and meet the unmet needs in women’s health.